Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 244

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 244
---
 625,000
ordinary shares represented by 62 Depositary Shares at an exercise price of $5,360.00 per warrant to an investor pursuant to
a waiver.

| 121 |

On March 27, 2023, following
shareholder approval, we effected a one-for-20 reverse split of our ordinary shares, and our ordinary shares began trading on AIM on a
split-adjusted basis as of such date. No fractional shares were issued in connection with the reverse stock split.

Concurrently with the reverse
split, and in an effort to bring the Depositary Shares price into compliance with NASDAQ’s minimum requirement for 500,000 listed
Depositary Shares, on March 27, 2023, we effected a ratio change in the number of our ordinary shares represented by the Depositary Shares
from 25 ordinary shares per Depositary Share to five ordinary shares per Depositary Share. No fractional Depositary Shares were issued.

Between March 27, 2023 and
December 31, 2024, we have issued 95,137,075 ordinary shares upon the exercise of pre-funded warrants, Series A Warrants and Series B
Warrants issued in the February Private Placement.

On May 26, 2023, we completed
the closing of the a registered direct offering with institutional investors of (1) 166,017,700 ordinary shares represented by 16,601
Depositary Shares, issuable upon the exercise of the Series C warrants, or Series C Warrants, at an exercise price of $400.00 per warrant,
(2) 110,675,600 ordinary shares represented by 11,059 Depositary Shares issuable upon the exercise of the Series D warrants, or Series
D Warrants, at an exercise price of $400.00 per warrant and, (3) 4,426,800 ordinary shares represented by 442 Depositary Shares issuable
upon the exercise of warrants issued to the placement agent in the offering at an exercise price of $375.00 per warrant.

On June 20, 2023, we issued
the Series C Warrants, Series D Warrants and warrants issued to the placement agent after receiving required shareholder approval of the
allotment of, and disapplication of pre-emption rights with respect to the ordinary shares to be issued under the warrants at our June
GM.

Between June 20, 2023, and
December 31, 2024, we have issued 166